Advocacy intelligence hub — real-time data for patient organizations
Radiogardase: FDA approved
Treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs2
Radiogardase
Heyl Chemisch-Pharmzeutische Fabrik GMBH & Co, KG
Rydapt
Novartis Pharmaceuticals Corporation
Rydapt
(RYDAPT)Orphan drugstandardNovartis Pharmaceuticals Corporation
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Midostaurin is a small molecule that inhibits multiple receptor tyrosine kinases. In vitro biochemical or cellular assays hav...
Browse all Systemic mastocytosis with associated hematologic neoplasm news →
Brenda Sandmaier
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
📍 SEATTLE, WA
Kyoo H. Lee, MD
Asan Medical Center
Maryam Fouladi, MD
COG Phase I Consortium
📍 COLUMBUS, OH
Andrew Kuykendall, MD, D.C
Moffitt Cancer Center
📍 DALLAS, TX
Ryotaro Nakamura
City of Hope Medical Center
📍 Duarte, California
Rachael Easton, MD, Ph.D., FNP-BC
Cogent Biosciences, Inc.
📍 TROY, MI
View all Systemic mastocytosis with associated hematologic neoplasm specialists →